A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2023-04-09
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-13 (study day 59); relationship: N
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 75); relationship: Y
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-19 (study day 95); relationship: Y
Data queries
No data queries.